Skip to main content
. 2019 Dec;25(43):4606–4612. doi: 10.2174/1381612825666191026170033

Fig. (2).

Fig. (2)

Matrine and oxymatrine reverse the inhibition of the hERG current after probucol treatment in hERG-HEK cells. (A) Voltage clamp protocol. (B) Representative hERG current traces recorded from a stably expressed hERG cell line in control conditions (a), in the presence of 100 μM probucol (b), in the presence of 100 μM probucol and 1 μM matrine (c), and in the presence of 100 μM probucol and 1 μM oxymatrine (d). (C-D) Normalized I-V relationships for the tail current before and after probucol treatment and rescue with 1 μM matrine and 1 μM oxymatrine. n=10, * p < 0.05 vs the control and + p <0.05 vs probucol. (E) The ratio of probucol, matrine, and oxymatrine voltage dependence peak tail current calculated using the function (I Drug-I Control)/I Control.